G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: Low toxicity and excellent outcomes in a 10-year analysis
Andrew M. Evens*, Jeffrey Cilley, Taylor Ortiz, Mrinal Gounder, Nanjiang Hou, Alfred Rademaker, Sarah Miyata, Kara Catsaros, Connie Augustyniak, Charles L. Bennett, Martin S. Tallman, Daina Variakojis, Jane N. Winter, Leo I. Gordon
Dive into the research topics of 'G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: Low toxicity and excellent outcomes in a 10-year analysis'. Together they form a unique fingerprint.